Publication | Closed Access

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

Sporadic CancerMedicineBrca Mutation CarriersPathologyCancer TreatmentCancer GeneticsOncologyRadiation OncologyPhase 1Cancer Research